On Jun. 13, 2011, Accuray announced it had completed its acquisition of TomoTherapy. The combination creates the premier radiation oncology company, offering best-in-class technologies to fight cancer.

Accuray offered radiation treatments tailored to the specific needs of each patient, ranging from high-precision radiosurgery for early-stage and localized disease to image-guided, intensity-modulated radiation therapy for more advanced disease sites throughout the body.

These complementary patient populations are treated by the same medical specialty, creating a broader base of sales relationships for the company to leverage. By bringing together the expertise and complementary resources of both companies, Accuray becomes a stronger organization with greater scale to invest in the R&D that will keep it on the leading edge of innovation.

With the closing of the transaction, Accuray’s installed base increases from 226 to more than 550 Systems, installed in 32 countries. Accuray’s total number of employees doubles to more than 1,000 worldwide. Corporate headquarters will remain in Sunnyvale, California.

TomoTherapy, founded in 1997 based on UW-Madison technology, had a Hi-Art system that spiraled around a patient firing radiation beams at cancerous tissue. The company had 350 employees.